New practice in semaglutide on type-2 diabetes and obesity: clinical evidence and expectation / 医学前沿
Frontiers of Medicine
; (4): 17-24, 2022.
Article
Dans En
| WPRIM
| ID: wpr-929201
Responsable en Bibliothèque :
WPRO
ABSTRACT
Obesity is an important risk factor of type 2 diabetes (T2D), which has become an important factor threatening human health. However, no perfect drug choice for obesity exists. Semaglutide is a kind of human glucagon-like peptide-1 (GLP-1) analog that promotes insulin secretion while inhibiting glucagon secretion through a glucose concentration-dependent mechanism. GLP-1 can also delay stomach emptying and suppress appetite to help lose weight. This review summarizes clinical evidence of the semaglutide effect on T2D and obesity and establishes expectations on future clinical trials for obesity treatment.
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Diabète de type 2
/
Peptides glucagon-like
/
Récepteur du peptide-1 similaire au glucagon
/
Hypoglycémiants
/
Motivation
/
Obésité
Type d'étude:
Risk_factors_studies
Limites du sujet:
Humans
langue:
En
Texte intégral:
Frontiers of Medicine
Année:
2022
Type:
Article